Welcome to our dedicated page for Calvert US Select Equity ETF news (Ticker: CVSE), a resource for investors and traders seeking the latest updates and insights on Calvert US Select Equity ETF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Calvert US Select Equity ETF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Calvert US Select Equity ETF's position in the market.
Morgan Stanley Investment Management has announced the liquidation of the Calvert US Select Equity ETF (CVSE), scheduled for October 20, 2025. The Fund will cease accepting Creation Unit orders and stop trading on NYSE Arca after market close on October 14, 2025.
Shareholders have two options: sell their shares on NYSE Arca until October 14, 2025, or remain invested until the Liquidation Date to receive a liquidating distribution. During the wind-down period, the Fund will transition its assets to cash and cash equivalents, which may impact its performance and investment objectives.
Investors should note that the liquidation will be considered a taxable event for shares not held in tax-deferred accounts, and remaining shareholders may face increased brokerage and transaction expenses.
FAQ
What is the current stock price of Calvert US Select Equity ETF (CVSE)?
